Clinical trials: Menopausal Symptoms
- Condition Menopausal Symptoms
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Menopause, Hot Flashes
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of…
- Conditions
- Menopause, Hot Flashes, Sleep Disorders
- Trial name
- NCT00256685
- Testing
- DVS-233 SR
- Volunteers
- 568 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Menopause
Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats.
- Trial name
- NCT00962585
- Testing
- S-equol
- Where
- 9 sites in United States, Australia
- Volunteers
- 169 people
- Sponsor
- Ausio Pharmaceuticals, LLC
Post Menopausal, Arthralgia
Breast Cancer Tumor Care Observational Programme
The purpose of this study is to investigate efficacy and tolerability under anastrozole (Arimidex) treatment.
- Trial name
- NCT00660244
- Testing
- anastrozole
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States
Menopause is a natural stage in a woman's life happening between ages 45 and 55. It is often associated with disruptive symptoms like hot flashes and sleep disturbances that can affect up to 8 out of 10 women and make daily life…
- Trial name
- RELIEF (NCT07490431)
- Testing
- No intervention
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Breast Cancer, Climacteric Symptoms
Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)
Postmenopausal women with a history of breast cancer often suffer from climacteric symptoms such as hot flushes and sweating episodes.
- Trial name
- NCT00408863
- Testing
- tibolone
- Volunteers
- 3,148 people
- Sponsor
- Organon and Co
Postmenopause
Effects of Wellnara on Climacteric Symptoms
Aim of this NIS is to obtain further information on efficacy, tolerability, and acceptance of Wellnara in a large user population under the conditions of routine medical practice.
- Trial name
- NCT00913926
- Testing
- E2/LNG oral (Wellnara, BAY86-5029)
- Where
- Germany
- Volunteers
- 749 people
- Sponsor
- Bayer
Hot Flashes
A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause
This study is for women in Germany who are going through menopause. They have symptoms including hot flashes and night sweats (also called vasomotor symptoms).
- Trial name
- GRACE (NCT07455812)
- Testing
- Fezolinetant
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Astellas Pharma Europe Ltd.
Vasomotor Symptoms
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with…
- Trial name
- NCT00421031
- Testing
- DVS-233 SR
- Where
- 41 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Stress Urinary Incontinence
Vesair Balloon Confirmatory Trial (VECTOR)
Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months.
- Trial name
- VECTOR (NCT03794206)
- Testing
- Vesair Balloon
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Solace Therapeutics, Inc.
Postmenopausal Period, Osteoporosis, Postmenopausal
Angeliq Regulatory Post Marketing Surveillance
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA).
- Trial name
- Angeliq rPMS (NCT01064453)
- Testing
- E2/DRSP (Angeliq, BAY86-4891)
- Where
- South Korea
- Volunteers
- 4,078 people
- Sponsor
- Bayer
Osteoporosis, Postmenopausal
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis.
- Trial name
- JULINA-CLIMA (NCT01386281)
- Testing
- E2 transdermal (Julina, BAY86-5435)
- Where
- Japan
- Volunteers
- 506 people
- Sponsor
- Bayer
Hot Flashes
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS).
- Trial name
- CANDLELIGHT (NCT07602530)
- Testing
- Fezolinetant
- Where
- 2 sites in Canada
- Volunteers
- 238 people
- Sponsor
- Astellas Pharma Europe Ltd.
Menopause, Vasomotor System
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS)…
- Trial name
- NCT00369434
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR)
- Where
- 34 sites in United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer